Biomaterials for the treatment of Alzheimer’s disease

Darya Hadavi, André A. Poot

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Scopus)
175 Downloads (Pure)


Alzheimer’s disease (AD) as a progressive and fatal neurodegenerative disease represents a huge unmet need for treatment. The low efficacy of current treatment methods is not only due to low drug potency but also due to the presence of various obstacles in the delivery routes. One of the main barriers is the blood–brain barrier. The increasing prevalence of AD and the low efficacy of current therapies have increased the amount of research on unraveling of disease pathways and development of treatment strategies. One of the interesting areas for the latter subject is biomaterials and their applications. This interest originates from the fact that biomaterials are very useful for the delivery of therapeutic agents, such as drugs, proteins, and/or cells, in order to treat diseases and regenerate tissues. Recently, manufacturing of nano-sized delivery systems has increased the efficacy and delivery potential of biomaterials. In this article, we review the latest developments with regard to the use of biomaterials for the treatment of AD, including nanoparticles and liposomes for delivery of therapeutic compounds and scaffolds for cell delivery strategies.
Original languageEnglish
Article number49
Pages (from-to)-
Number of pages10
JournalFrontiers in bioengineering and biotechnology
Issue number49
Publication statusPublished - 2016


Dive into the research topics of 'Biomaterials for the treatment of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this